Compounding Pharmacies for Chemotherapy Agents
1.0 CE Credit Hour / Philip Bergman, DVM, MS, PhD, DACVIM
Philip Bergman, DVM, MS, PhD, DACVIM
Dr. Bergman is the Director of Clinical Studies for Mars Veterinary Health. He is the principal veterinary investigator for the fully licensed canine melanoma vaccine (Oncept). Dr. Bergman is an adjunct faculty member of the Memorial Sloan-Kettering Cancer Center. Prior to Dr. Bergman joining VCA, he served as the Chief Medical Officer for BrightHeart Veterinary Centers from July 2007 to August 2011; from 1999 to June 2007 he was the head of the Donaldson-Atwood Cancer Center at AMC. After finishing veterinary school from Colorado State in 1990, he was an intern at Kansas State (90-91) and returned to CSU for his medical oncology residency (91-94) and then completed a PhD Fellowship in human cancer biology from the M.D. Anderson Cancer Center in Houston (94-99). He was previously Chair of the ACVIM Board of Regents and President of the Veterinary Cancer Society. Dr. Bergman has been an veterinary oncologist at Katonah Bedford Veterinary Center since 2007.
Overview:
The use of compounding in veterinary medicine has skyrocketed in the last 10 years. Unfortunately, there have been numerous compounding pharmacy debacles leading to serious injury and/or death for human and veterinary patients. In response to these debacles, Congress passed the DQSA or Drug Quality & Security Act in 2013. This lecture will review the various word salad acronyms associated with compounding. We will also review the numerous publications in the area which definitively show that not all compounding pharmacies are created equal, which can have profound impact on our medication decisions we make for our patients.
Learning Objectives:
- Become more fluent in the various FDA designations for differing types of compounding pharmacies
- Understand the differences between 503A traditional compounding pharmacies and 503B “outsourcing facilities”
- Become more fluent in the scientific literature that documents amount of drug delivered for both cytotoxic chemotherapies as well as numerous other medications outside the oncology space
This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.
